T
TAK
Takeda Pharm
15.06
0.04+0.27%After Hours: 15.15 +0.09 +0.60%18:58 09/19 EDT
OPEN/PREV CLOSE15.03/15.02
TODAY RANGE15.03-15.10
VOL1.82M
MARKET CAP47.56B
52 WEEK RANGE12.51-15.69
AVG VOL (3M)3.73M
% TURNOVER0.06%
TURNOVER--
P/E (TTM)50.59
% RANGE0.47%
EPS(TTM)0.2977
P/E(FORWARD)29.90
P/B0.9932
BVPS15.16
DIVIDEND0.6651
P/S1.544
BETA--
DIV YIELD4.42%
FREE FLOAT MKT CAP47.56B
SHARES OUTSTANDING3.16B
NEXT EARNINGS10/29-11/03
FREE FLOAT3.16B
LOT SIZE1
EX-DATE03/31/2025
News
Press Releases
Financial Reports
Profile
Seeking Alpha·1d ago
Novavax: Endlessly Frustrating, Endlessly Fascinating - Warrants Rating Upgrade
Seeking Alpha·6d ago
SA Asks: Which biotechs could be acquired by year's end?
TipRanks·09/12 10:15
Protagonist Therapeutics initiated with an Outperform at Leerink
Seeking Alpha·09/11 14:10
Takeda names Lilly's Rhonda Pacheco as President of the U.S. unit
Reuters·09/11 12:45
TAKEDA APPOINTS RHONDA PACHECO PRESIDENT OF THE U.S. BUSINESS UNIT
TipRanks·09/09 11:25
Alkermes price target lowered to $43 from $45 at Needham
TipRanks·09/09 11:25
Harmony Biosciences price target lowered to $48 from $49 at Needham
TipRanks·09/09 10:40
Alkermes price target raised to $35 from $34 at JPMorgan
TipRanks·09/09 08:55
Promising Phase 3 Results for Takeda’s Oveporexton Boost Buy Rating
TipRanks·09/08 18:55
Takeda Pharmaceutical’s Promising Narcolepsy Treatment Drives Buy Rating
TipRanks·09/08 17:40
Jefferies says stage set for Centessa to differentiate in narcolepsy
TipRanks·09/08 09:20
Takeda reports FirstLight, RadiantLight studies met all endpoints
Same Industry
Name/Symbol
Change%
Price